What are the ESMO guidelines for hairy cell leukemia (HCL) treatment?

Updated: Sep 16, 2018
  • Author: Emmanuel C Besa, MD; Chief Editor: Koyamangalath Krishnan, MD, FRCP, FACP  more...
  • Print

Overall, ESMO guidelines are in agreement with NCCN, but include the following additional recommendations for treatment of refractory disease [16] :

  • Splenectomy may be indicated in patients with symptomatic splenomegaly (>10 cm below the costal margin) and low-level bone marrow infiltration
  • Allogeneic hematopoietic stem cell transplantation
  • Moxetumomab pasudotox
  • Fludarabine with rituximab
  • Bendamustine with rituximab

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!